Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals
CRESTWOOD, Ky. and WALTHAM Mass., 16 juin 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), une société biopharmaceutique de stade clinique axée sur le développement de nouveaux...
The Rosen Law Firm PA
REV DEADLINE: Rosen, a Highly Ranked Law Firm, Reminds Revlon, Inc. Investors of Important July 15th Deadline in Securities Class Action – REV
NEW YORK, June 15, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Revlon, Inc. (NYSE: REV) from March 12, 2015 through March 28,...
Silk Road Medical
ROADSTER-2 Demonstrates Compelling Patient Outcomes with Strong Safety Profile
Final Results Presented in Late-Breaking Sessionat Society for Vascular Surgery 2019 Vascular Annual Meeting NATIONAL HARBOR, Md., June 15, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq:...
Canadian National Railway
Teamsters Rail Traffic Controllers Ratify New CN Agreement
MONTREAL, June 15, 2019 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) announced today that following the tentative agreement reached in May, the Teamsters Canada Rail Conference Rail Canada Traffic...
Editas Medicine, Inc.
Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
IND-enabling activities initiated for EDIT-301, a potentially best-in-class experimental medicine for the treatment of sickle cell disease and beta-thalassemia CAMBRIDGE, Mass., June 15, 2019 ...
Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting
SOUTH SAN FRANCISCO, Calif., June 15, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial...
Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress
CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Forty Seven, Inc.
Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
-- 5F9 Well-Tolerated in Combination with Rituximab ---- Durable Responses Observed in DLBCL and Indolent Lymphoma; Median Duration of Response Not Yet Reached ---- Overall Response Rate (ORR) of 36%...
Yleiselektroniikka Oyj
JULKINEN OSTOTARJOUS YLEISELEKTRONIIKKA OYJ:N OSAKKEISTA
JULKINEN OSTOTARJOUS YLEISELEKTRONIIKKA OYJ:N OSAKKEISTA PÖRSSITIEDOTE 15.6.2019 KLO 15:30 Preato Capital AB on 14.6.2019 hankkinut omistukseensa 1.327.224...
Fraser Institute
Fraser Institute News Release: Fraser Institute ranks Alberta high schools, elementary schools in annual Report Cards
CALGARY, Alberta, June 15, 2019 (GLOBE NEWSWIRE) -- The Fraser Institute today released its annual rankings of Alberta high schools and elementary schools, allowing parents to compare the academic...